Anandia Laboratories Raises Investment from Genome BC

Anandia Laboratories Inc., a Vancouver, Canada-based cannabis biotechnology company, raised an investment from Genome BC’s Industry Innovation (I²) Program.

The amount of the deal was not disclosed.

The company intends to use the funds to expand its analytical testing services including ramping up sales and marketing activities with several key hires, as well as to accelerate the identification of high-value genetic traits enabling the commercialization of optimized cannabis varieties.

Led by co-founder and CEO Dr. Jonathan Page, an authority on cannabis biochemistry and genomics, Anandia Labs providing testing services to clients licensed under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), including Licensed Producers (LPs) and patients.



Join the discussion